Affordable Access

Access to the full text

Prostaglandin E2 alteration in contraceptive consumers: as a risk factor for inflammatory diseases

Authors
  • Sanjary Pour, Maryam1
  • Fallah, Soudabeh1
  • Rabbani Chadegani, Azra2
  • 1 Biochemistry Department of Tehran University of Medical Sciences, Hemmat High Way, Tehran, Iran , Tehran (Iran)
  • 2 University of Tehran, Department of Biochemistry, Institute of Biochemistry and Biophysics, Tehran, Iran , Tehran (Iran)
Type
Published Article
Journal
Archives of Gynecology and Obstetrics
Publisher
Springer-Verlag
Publication Date
Dec 09, 2012
Volume
287
Issue
5
Pages
1031–1037
Identifiers
DOI: 10.1007/s00404-012-2661-3
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposeThe aim of this study was to evaluate the effect of oral combined contraceptive pills on Prostaglandin E2 levels and lipid profiles.MethodsThe enzyme-linked immune absorbent assay method and spectrophotometric assay were used for the evaluation of PGE2 levels and lipid profiles, respectively, in 50 healthy women with normal menstrual cycles who served as the control group and 50 women taking contraceptive pill.ResultsThe data obtained for serum Prostaglandin E2, LDL-C, and cholesterol concentrations in contraceptive pill consumers were significantly upper (P = 0.04, 0.002, and 0.05, respectively) than control group. The age of contraceptive pill consumption and the duration of pill intake beyond 36 months had no significant effect on the prostaglandin E2 concentration.ConclusionIt is suggested that the increase of Prostaglandin E2 and atherogenic lipid levels may be related to their probable effects in response to various pathological and physiological properties of COCs.

Report this publication

Statistics

Seen <100 times